Daniel J. DeAngelo, MD, PhD, associate professor at the Harvard School of Medicine and a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, highlighted the 4 FDA approvals in the last year for the treatment of patients with acute myeloid leukemia.
Daniel J. DeAngelo, MD, PhD, associate professor at the Harvard School of Medicine and a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, highlighted the 4 FDA approvals in the last year for the treatment of patients with acute myeloid leukemia (AML).
Midostaurin (Rydapt) was the first FLT3 inhibitor approved for treatment in combination with chemotherapy. This has become the standard of care for patients with AML. CPX-351 (Vyzeos) was also approved as a treatment option for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-relatedchanges, says DeAngelo.
Gemtuzumab ozogamicin (Mylotarg) was FDA approved more than a decade ago, but has made a reappearance again with a new FDA approval for patients with CD33-positive AML. Dana-Farber is mirroring the ALFA-0701 trial, on which this approval was based. DeAngelo says data showed an improvement in event-free and overall survival with the addition of this drug to standard treatment.
Enasidenib was also approved in this landscape for patients with IDH2 mutations in the relapsed/refractory setting. This is still being investigated in ongoing trials.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More